Vol 9, No 2 (2024)
Letter to the Editor
Published online: 2024-06-28
Senolytic effect of canagliflozin, a new possible line of treatment for age-related diseases
1
, 2, 2
, 2, 2
DOI: 10.5603/mrj.101197
Medical Research Journal 2024;9(2):245-246.
Abstract
Not available
Keywords: canagliflozinsenescent cellsage-related diseasesdiabetespharmacotherapy
References
- Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24): 2295–2306.
- Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019; 140(9): 739–750.
- Ohkuma T, Van Gaal L, Shaw W, et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes Obes Metab. 2020; 22(4): 530–539.
- Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021; 143(18): 1735–1749.
- Katsuumi G, Shimizu I, Suda M, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging. 2024 [Epub ahead of print].
- McHugh D, Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol. 2018; 217(1): 65–77.